Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Yinma Jiedu is a Traditional Chinese Medicine (TCM) granule formulation developed by the Guangdong Provincial Hospital of Chinese Medicine. It is primarily investigated as an adjunctive therapy to standard antibiotics for the treatment of community-acquired pneumonia (CAP). The formula is designed based on TCM principles to clear heat, detoxify, and ventilate the lungs, aiming to mitigate the inflammatory response and improve clinical recovery in patients with pulmonary infections. It is currently being evaluated in multicenter, randomized, double-blind, placebo-controlled clinical trials to establish its efficacy and safety profile in hospitalized patients.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Yinma Jiedu.